GNI Group Valuation
Is 2160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2160 (¥2786) is trading above our estimate of fair value (¥1756.42)
Significantly Below Fair Value: 2160 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2160?
Key metric: As 2160 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 2160's PE Ratio? | |
|---|---|
| PE Ratio | 19.4x |
| Earnings | JP¥7.19b |
| Market Cap | JP¥141.93b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 14.5x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does 2160's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 48.1x | ||
4974 Takara Bio | 141.9x | 25.2% | JP¥129.8b |
4587 PeptiDream | 19.3x | -9.0% | JP¥330.5b |
2929 Pharma Foods International | 8.4x | n/a | JP¥27.6b |
177A Kohjin Bio | 22.7x | 25.7% | JP¥9.1b |
2160 GNI Group | 19.4x | 23.4% | JP¥141.9b |
Price-To-Earnings vs Peers: 2160 is good value based on its Price-To-Earnings Ratio (19.4x) compared to the peer average (48.1x).
Price to Earnings Ratio vs Industry
How does 2160's PE Ratio compare vs other companies in the Asian Biotechs Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 2160 is good value based on its Price-To-Earnings Ratio (19.4x) compared to the Asian Biotechs industry average (32.6x).
Price to Earnings Ratio vs Fair Ratio
What is 2160's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 19.4x |
| Fair PE Ratio | 24.4x |
Price-To-Earnings vs Fair Ratio: 2160 is good value based on its Price-To-Earnings Ratio (19.4x) compared to the estimated Fair Price-To-Earnings Ratio (24.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | JP¥2,786.00 | JP¥3,850.00 +38.2% | 3.9% | JP¥4,000.00 | JP¥3,700.00 | n/a | 2 |
| Nov ’25 | JP¥3,025.00 | JP¥3,850.00 +27.3% | 3.9% | JP¥4,000.00 | JP¥3,700.00 | n/a | 2 |
| Oct ’25 | JP¥3,035.00 | JP¥3,850.00 +26.9% | 3.9% | JP¥4,000.00 | JP¥3,700.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Shionogi
JP¥1.8t
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan.
4507
JP¥2,091.50
7D
-1.8%
1Y
-10.0%
Tsumura
JP¥373.7b
Manufactures and sells pharmaceutical products from crude drugs derived from plants and other natural products in Japan and internationally.
4540
JP¥4,921.00
7D
-0.7%
1Y
81.2%
ASKA Pharmaceutical HoldingsLtd
JP¥57.8b
Through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan.
4886
JP¥2,037.00
7D
-4.1%
1Y
14.8%